India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia  | Date: 2022-01-18

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine
  • Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials.
  • If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine.

Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is reportedly working on an Omicron-specific vaccine that is likely to be ready in a couple of months. The potential vaccine might undergo a small trial in India before being exported as a booster shot or a standalone vaccine.

The apparent mRNA vaccine, produced specially to counter the recent Omicron variant, will be tested on humans first to know its efficiency and immunogenic soon.

The company had issued a press statement regarding the vaccine back in September 2021. It stated that the DCGI (Drug Controller General of India) had already approved the Phase II and Phase III study for the mRNA-based COVID-19 vaccine.

Gennova has already filed its Phase I study with the Central Drugs Standard Control Organization (CDSCO). Even the SEC (Subject Expert Committee) has deemed the company’s HGCO19 vaccine candidate as tolerable, safe, and immunogenic among the participants.

Meanwhile, Gennova has claimed that the Phase II and III study is being conducted across 15 and 27 sites in India, essentially using the DBT-ICMR trail network for its clinical study. If approved the vaccine for an emergency use authorization (EUA), it would be India’s first mRNA COVID-19 vaccine.

In other news, a recent Israeli trial found that Pfizer’s fourth dose is still insufficient to counter the Omicron variant. Although the fourth dose managed to increase the COVID-19 antibodies count in the participants, it was still “not good enough” to completely ward off the Omicron variant.

Some experts believe that Pfizer’s fourth dose could be used for those who are at the highest risk, but also suggested that it would be ideal to give the shot to senior citizens instead of to those just over the age of 60.

Source credits –

https://www.freepressjournal.in/india/punes-gennova-biopharmaceuticals-developing-covid-19-vaccine-for-omicron-variant

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Facebook-owner Meta to share more data on political advertisements

Facebook-owner Meta to share more data on political advertisements

By Nikita Chaurasia

Facebook-parent Meta Platforms Inc has recently announced that it would provide additional data from its public ad database regarding the targeting decisions made by publishers running social and political-issue advertising. As a part of the expan...

Massachusetts finds first 2022 monkeypox case in the United States

Massachusetts finds first 2022 monkeypox case in the United States

By Nikita Chaurasia

The Massachusetts Department of Public Health has recently reported the first case of a rare infection called monkeypox in a man who recently visited Canada. According to Boston’s public department, the identified case is no threat to the pu...

Russia denies plans of blocking YouTube & cutting off from the internet

Russia denies plans of blocking YouTube & cutting off from the internet

By Nikita Chaurasia

The Digital Development Minister of Russia has reportedly stated that the country is not planning to block Google’s video streaming platform YouTube as such a move would affect its users and will therefore be avoided.  It is worth notin...

Indian food delivery giant Swiggy to buy Dineout from Times Internet

Indian food delivery giant Swiggy to buy Dineout from Times Internet

By Nikita Chaurasia

Swiggy, an Indian food delivery giant, has recently announced an agreement with Times Internet to buy Dineout, a dining and restaurant technology platform. Swiggy will use the acquisition to enter the dining out (non-delivery) market, where it will c...

Grocery delivery platform Instacart files for U.S. stock market debut

Grocery delivery platform Instacart files for U.S. stock market debut

By Nikita Chaurasia

Instacart, a grocery delivery service, has announced that it has submitted a provisional registration statement with the Securities and Exchange Commission (SEC), clearing the way for the company to list its shares on the U.S. stock exchange. The ...